Non-Invasive markers for hepatic fibrosis

BMC Gastroenterology

Volumn 11, Issue , 2011, Pages

  Baranova, Ancha ^a,b   Lal, Priyanka ^a,b   Birerdinc, Aybike ^a,b   Younossi, Zobair M ^a,c  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; ELASTIN; FIBRONECTIN; HYALURONIC ACID; LAMININ; METALLOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTEOGLYCAN; REACTIVE OXYGEN METABOLITE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNDULIN;

ACOUSTIC RADIATION FORCE IMPULSE; ALCOHOL CONSUMPTION; ANALYTIC METHOD; APOPTOSIS; BLOOD LEVEL; CELL PROLIFERATION; CHOLESTASIS; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL RESEARCH; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DYSLIPIDEMIA; ELASTOGRAPHY; FIBROGENESIS; HEALING; HEPATITIS C; HOST PATHOGEN INTERACTION; HUMAN; INSULIN RESISTANCE; INTRAHEPATIC CHOLESTASIS; IRON OVERLOAD; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MYOFIBROBLAST; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATIENT CARE; PHAGOCYTOSIS; PROCESS DEVELOPMENT; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCORING SYSTEM; TREATMENT PLANNING; VIRUS HEPATITIS; LIVER CIRRHOSIS; METABOLISM;

BIOLOGICAL MARKERS; HUMANS; LIVER CIRRHOSIS;

EID: 80051650764     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-11-91     Document Type: Review

References (103)

1. Schiff ER, Lee SS, Chao YC, Kew-Yoon S, Bessone F, Wu SS, Kryczka W, Lurie Y, Gadano A, Kitis G, Beebe S, Xu D, Tang H, Iloeje U. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2010,
2. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010, 52(3):886-893. 10.1002/hep.23785, 20683932.
3. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, Jones DE, Burt AD, Kirby JA. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 2008, 88:112-123. 10.1038/labinvest.3700704, 18059363.
4. Brenner DA. Molecular pathogenesis of liver fibrosis. Transactions of the American Clinical and Climatological Association 2009, 120:361-368. 2744540, 19768189.
5. Malhi H, Guicciardi ME, Gregory J, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev 2010, 90:1165-1194. 10.1152/physrev.00061.2009, 2943859, 20664081.
6. Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klaunig JE. Role of the Kupffer Cell in Mediating Hepatic Toxicity and Carcinogenesis. Toxicological Sciences 2006, 96(1):2-7. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008, 88(1): 125-172, 10.1093/toxsci/kfl173, 17122412.
7. Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009, 25(3):223-229. 10.1097/MOG.0b013e3283279668, 2883289, 19396960.
8. Bataller R, Brenner DA. Liver Fibrosis. The Journal of Clinical Investigation 2005, 115(2):209-218. 546435, 15690074.
9. Fontana L, Jerez D, Rojas-Valencia L, Solis-Herruzo JA, Greenwel P, Rojkind M. Ethanol induces the expression of alpha1(I) procollagen mRNA in a co-culture system containing a liver stellate cell-line and freshly isolated hepatocytes. Biochim Biophys Acta 1997, 1362:135-144.
10. Purohit V, Brenner DA. Mechanisms of Alcohol-Induced Hepatic Fibrosis: A Summary of the Ron Thurman Symposium. Hepatology 2006, 43(4):872-878. 10.1002/hep.21107, 16502397.
11. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008, 15:91-101. 10.1016/j.pathophys.2008.05.001, 18602801.
12. Diehl AM. Nonalcoholic steatosis and steatohepatitis, Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002, 282:G1-G5.
13. Rahmouni K, Haynes WG. Endothelial effects of leptin: implications in health and diseases. Curr Diab Rep 2005, 5:260-266. 10.1007/s11892-005-0020-5, 16033675.
14. Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B, Romagnani P, Milani S, Gines P, Colmenero J, Parola M, Gelmini S, Tarquini R, Laffi G, Pinzani M, Marra F. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006, 169:2042-2053. 10.2353/ajpath.2006.060081, 1762467, 17148667.
15. Glaser SS, Gaudio E, Miller T, Alvaro D, Alpini G. Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med 2009, 25; 11:e7.
16. Bataller R, Yang L, Brenner DA. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004, 40:1151-1159. 10.1002/hep.20427, 15389867.
17. Martin-Vílchez S, Sanz-Cameno P, Rodriguez-Munoz Y, Majano PL, Molina-Jimenez F, Lopez-Cabrera M, Moreno-Otero R, Lara-Pezzi E. The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. Hepatology 2008, 47(6):1872-1883. 10.1002/hep.22265, 18449922.
18. Lin W, Wu G, Li S, Weinberg EM, Kumthip K, Peng LF, Mendez-Navarro J, Chen WC, Jilg N, Zhao H, Goto K, Zhang L, Brockman MA, Schuppan D, Chung RT. HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NF{kappa}B. J Biol Chem 2010,
19. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006, 12(23):3682-3694.
20. West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology 2010, 139(4):1230-7. Epub 2010 Jun 12, 10.1053/j.gastro.2010.06.015, 20547160.
21. Terjung B, Lemnitzer I, Dumoulin FL, Effenberger W, Brackmann HH, Sauerbruch T, Spengler U. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003, 67(3):138-45.
22. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435. 10.1002/hep.1840010511, 7308988.
23. Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006, 55:569-578. 10.1136/gut.2005.084475, 1856155, 16531536.
24. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. Journal of Hepatology 1991, 13:372-4. 10.1016/0168-8278(91)90084-O, 1808228.
25. Desmet V J, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994, 19:1513-20. 10.1002/hep.1840190629, 8188183.
26. Ratnakar KS, Sudha S. Image analysis in the evaluation of chronic hepatitis. Bahrain Medical Bulletin 2001,
27. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24(2):289-293.
28. Poynard T, Hepatitis B, Hepatitis C. management and treatment. A Martin Dunitz Book 2002, Taylor & Francis, United Kingdom, 1.
29. Franciscus A. HCV Diagnostic tools: Grading and staging a liver biopsy. 2010, HCSP, Version 2.4.
30. Poynard T, Ratziu V, Benmanov Y, Martino VD, Bedossa P, Opolon P. Fibrosis in patients with hepatitis C: Detection and significance. Semin Liver Dis 2000, 20(1):0047-0056.
31. Bedossa P, Carrat F. Liver fibrosis: screening is not staging. J Hepatol 2009, 50(6):1268-1269. 10.1016/j.jhep.2009.02.011, 19395116.
32. Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis 2007, 11(1):17-23. vii, 10.1016/j.cld.2007.02.002, 17544969.
33. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, Benhamou Y, Bourlière M, de Ledinghen V, . FibroPaca Group Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007, 53(9):1615-22. 10.1373/clinchem.2007.085795, 17634213, FibroPaca Group.
34. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38(6):1449-57.
35. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41(1):48-54. 10.1002/hep.20506, 15690481.
36. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008, 134(4):960-74. 10.1053/j.gastro.2008.01.034, 18395077.
37. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P, . FIBROSTIC study group Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010, 53(6):1013-21. 10.1016/j.jhep.2010.05.035, 20850886, FIBROSTIC study group.
38. Fraquelli M, Rigamonti C, Casazza G, Donato MF, Ronchi G, Conte D, Rumi M, Lampertico P, Colombo M. Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol 2011, 54(4):621-8. 10.1016/j.jhep.2010.07.017, 21146243.
39. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128(2):343-50. 10.1053/j.gastro.2004.11.018, 15685546.
40. Castéra L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, Couzigou P, de Lédinghen V. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010, 51(3):828-35.
41. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008, 134. Gastroenterology 2008, 134(6):1670-1681. 10.1053/j.gastro.2008.03.001, 18471546.
42. Talwalkar JA. Antifibrotic therapies--emerging biomarkers as treatment end points. Nat Rev Gastroenterol Hepatol 2010, 7(1):59-61. 10.1038/nrgastro.2009.197, 20051972.
43. Takahashi H, Ono N, Eguchi Y, Eguchi T, Kitajima Y, Kawaguchi Y, Nakashita S, Ozaki I, Mizuta T, Toda S, Kudo S, Miyoshi A, Miyazaki K, Fujimoto K. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int 2010, 30(4):538-45. 10.1111/j.1478-3231.2009.02130.x, 19874490.
44. Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, Saito S, Nakajima A. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse lastography. Radiology 2010, 256(2):640-7. 10.1148/radiol.10091662, 20529989.
45. Rifai K, Cornberg J, Mederacke I, Bahr MJ, Wedemeyer H, Malinski P, Bantel H, Boozari B, Potthoff A, Manns MP, Gebel M. Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). Dig Liver Dis 2011,
46. Kuroda H, Kakisaka K, Tatemichi Y, Sawara K, Miyamoto Y, Oikawa K, Miyasaka A, Takikawa Y, Masuda T, Suzuki K. Non-invasive evaluation of liver fibrosis using acoustic radiation force impulse imaging in chronic hepatitis patients with hepatitis C virus infection. Hepatogastroenterology 2010, 57(102-103):1203-7.
47. Taouli B, Ehman RL, Reeder SB. Advanced MRI methods for assessment of chronic liver disease. AJR 2009, 193:14-27. 10.2214/AJR.09.2601, 2989464, 19542391.
48. Rouviere O, Yin M, Dresner MA, Rossman PJ, Burgart LJ, Fidler JL, Ehman RL. MR elastography of the liver: preliminary results. Radiology 2006, 240(2):440-448. 10.1148/radiol.2402050606, 16864671.
49. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, Fidler JL, Ehman RL, Yin, M. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007, 5:1207-1213. 10.1016/j.cgh.2007.06.012, 2276978, 17916548.
50. Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, Peeters F, ter Beek LC, Rahier J, Sinkus R, Horsmans Y, Van Beers BE. Magnetic resonance elastography for the non invasive staging of liver fibrosis. Gastroenterology 2008, 135(1):32-40. 10.1053/j.gastro.2008.03.076, 18471441.
51. Zhou K, Lu LG. Assessment of fibrosis in chronic liver diseases. Journal of Digestive Diseases 2009, 10(1):7-14. 10.1111/j.1751-2980.2008.00356.x, 19236541.
52. Park SH, Kim CH, Kim DJ, Suk KT, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB. Usefulness of multiple biomarkers for the prediction of significant fibrosis in chronic hepatitis B. J Clin Gastroenterol 2011, 45(4):361-5. 10.1097/MCG.0b013e31820d3458, 21301354.
53. Grigorescu M. Noninvasive Biochemical Markers of Liver Fibrosis. J Gastrointestin Liver Dis 2006, 15(2):149-159.
54. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver dependent malfunction tests. Clin Chim Acta 2007, 381:107-113. 10.1016/j.cca.2007.02.038, 17399697.
55. Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, Karsdal MA. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 2010, 3(1):5. 10.1186/1755-1536-3-5, 2860343, 20359335.
56. Lieber CS, Weiss DG, Paronetto F, . Veterans Affairs Cooperative Study 391 Group Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res 2008, 32(6):1031-9. 10.1111/j.1530-0277.2008.00664.x, 18422837, Veterans Affairs Cooperative Study 391 Group.
57. Jarcuska P, Janicko M, Veseliny E, Jarcuska P, Skladany L. Circulating markers of liver fibrosis progression. Clinica Chimica Acta 2010, 411(15-16):1009-1017.
58. Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. Journal of Signal Transduction 2010, 2010:1-7.
59. Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A. Dual expression of matrix protease -2 and membrane type I-matrix proteinase in fibrotic human livers. Hepatology 1997, 26:1521-1529. 10.1002/hep.510260620, 9397993.
60. Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as non invasive markers of liver disease inchronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999, 44:624-630. 10.1023/A:1026630129025, 10080160.
61. Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1999, 14:138-145.
62. Hayasaka A, Suzuki N, Fujimoto N, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996, 24:1058-1062. 10.1002/hep.510240513, 8903375.
63. Badra G, Lotfy M, El-Refaie A, Obada M, Abdelmonem E, Kandeel S, Fathy A. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. Acta Microbiol Immunol Hung 2010, 57(1):29-42. 10.1556/AMicr.57.2010.1.3, 20350877.
64. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, Dienes HP, Lohse AW. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001, 8(6):430-7. 10.1046/j.1365-2893.2001.00314.x, 11703574.
65. Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Non-invasive markers to predict the liver fibrosis in non alcoholic fatty liver disease. Liver Int 2006, 26:864-871. 10.1111/j.1478-3231.2006.01312.x, 16911470.
66. Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P, Pradier C, Barjoan EM, Demuth N, Longo F, Rampal P. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000, 12(9):989-993. 10.1097/00042737-200012090-00004, 11007134.
67. Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM, Hellerbrand C, Mueller T, Berg T, Weiskirchen R, Trautwein C, Wasmuth HE. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol 2009, 50(2):370-6. 10.1016/j.jhep.2008.09.016, 19070929.
68. Kropf J, Gressner AM, Negwer A. Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases. Clinical Chemistry 1988, 34:2026-2030.
69. Korner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996, 25:684-688. 10.1016/S0168-8278(96)80239-X, 8938546.
70. Gressner OA, Gressner AM. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 2008, 28:1065-1079. 10.1111/j.1478-3231.2008.01826.x, 18783549.
71. Camps J, Marsillach J, Joven J. Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World J Gastroenterol 2009, 15(16):1929-1933. 10.3748/wjg.15.1929, 2675081, 19399923.
72. Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L, Joven J. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002, 48(2):261-268.
73. Molleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL, Tornoe I, Schlosser A, Kloppel G, Schmiegel W, Meyer HE, Holmskov U, Stühler K. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology 2009, 49(4):1257-1266. 10.1002/hep.22764, 2895500, 19177598.
74. Haukeland JW, Schreiner LT, Lorgen I, Frigstad SO, Bang C, Raknerud N, Konopski Z. AST/ALT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis. Scand J Gastroenterol 2008, 43(10):1241-1248. 10.1080/00365520802158614, 18609128.
75. Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician 2005, 71(6):1105-1110.
76. Nguyen-Khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly JP, Brevet M, Grignon P, Lion S, Le Page L, Dupas JL. Assessment of asymptomatic liver fibrosis in alcoholic patients using FibroScan: prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther 2008, 28(10):1188-98. 10.1111/j.1365-2036.2008.03831.x, 18705692.
77. Lu LG, Zeng MD, Mao YM, Li JQ, Qiu DK, Fang JY, Cao AP, Wan MB, Li CZ, Ye J, Cai X, Chen CW, Wang JY, Wu SM, Zhu JS, Zhou XQ. Relationship between clinical and pathologic findings in patients with chronic liver diseases. World J Gastroenterol 2003, 9(12):2796-2800.
78. DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re V. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010, 10:116. 10.1186/1471-2334-10-116, 2876168, 20465840.
79. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011, 53(3):726-36. 10.1002/hep.24105, 21319189.
80. Rossi E, Adams LA, Bulsara M, Jeffrey GP. Assessing liver fibrosis with serum marker models. Clin Biochem Rev 2007, 28(1):3-10. 1904421, 17603636.
81. Guechot J, Lasnier E, Sturm N, Paris A, Zarski JP, . ANRS HC EP 23 Fibrostar study group Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta 2010, 411(1-2):86-91. 10.1016/j.cca.2009.10.011, 19850017, ANRS HC EP 23 Fibrostar study group.
82. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, . APRICOT Clinical Investigators Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317-1325. 10.1002/hep.21178, 16729309, APRICOT Clinical Investigators.
83. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007, 46(1):32-36. 10.1002/hep.21669, 17567829.
84. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. J Hepatology 2005, 43(1):78-84.
85. Braden B, Faust D, Sarrazin U, Zeuzem S, Dietrich CF, Caspary WF, Sarrazin C. 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2005, 21(2):179-85. 10.1111/j.1365-2036.2005.02317.x, 15679768.
86. Lalazar G, Pappo O, Hershcovici T, Hadjaj T, Shubi M, Ohana H, Hemed N, Ilan Y. A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT. J Viral Hepat 2008, 15(10):716-728. 10.1111/j.1365-2893.2008.01007.x, 2658713, 18638013.
87. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderateto- advanced liver fibrosis in chronc hepatitis C patients. J Hepatol 2004, 41:935-942. 10.1016/j.jhep.2004.08.008, 15582126.
88. Patel K, Nelson DR, Rockey DC, Afdhal NH, Smith KM, Oh E, Hettinger K, Vallee M, Dev A, Smith-Riggs M, McHutchison JG. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol 2008, 6(2):242-247. 10.1016/j.cgh.2007.11.009, 18187364.
89. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G, Speers D, Jeffrey G. FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Validation of the Clin Chem 2003, 49(3):450-454.
90. Imbert-Bismut F, Messous D, Thibault V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004, 42(3):323-333. 10.1515/CCLM.2004.058, 15080567.
91. Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterology 2010, 10:103. 10.1186/1471-230X-10-103, 2944336, 20828377.
92. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007, 45:297-306. 10.1002/hep.21520, 17256741.
93. Sebastiani G, Vario A, Guido M, Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008, 15(3):212-218.
94. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998, 28:439-446. 10.1016/S0168-8278(98)80318-8, 9551682.
95. Cales P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC, Dib N, Moal V, Macchi L, Chevailler A, Michalak S, Hunault G, Chaigneau J, Sawadogo A, Lunel F. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol 2008, 32(6 Suppl 1):40-51.
96. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854. 10.1002/hep.21496, 17393509.
97. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ, . European Liver Fibrosis Group Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713. 10.1053/j.gastro.2004.08.052, 15578508, European Liver Fibrosis Group.
98. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Non-invasive markers of fibrosis in non-alcoholic fatty liver disease: validating the European Liver Fibrosis panel and exploring simple markers. Hepatology 2008, 47(2):455-460.
99. Callewaert N, Vlierberghe HV, Hecke AV, Laroy W, Delanghe J, Contreras R. Non invasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nature Medicine 2004, 10:429-434. 10.1038/nm1006, 15152612.
100. Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. Alteration of protein glycosylation in liver diseases. J Hepatol 2009, 50(3):592-603. 10.1016/j.jhep.2008.12.010, 19157620.
101. Younossi ZM, Baranova A, Stepanova M, Page S, Calvert VS, Afendy A, Goodman Z, Chandhoke V, Liotta L, Petricoin E. Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. J Proteome Res 2010, 9(6):3218-24. 10.1021/pr100069e, 20441224.
102. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, Ferrari A, Alberti A. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006, 44(4):686-93. 10.1016/j.jhep.2006.01.007, 16490278.
103. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Guido M, Bourliere M, Noventa F, Alberti A. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009, 49(6):1821-7. 10.1002/hep.22859, 19291784.